Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet B McGill

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
Postgraduate Medicine|April 1, 2009
Improving microvascular outcomes in patients with diabetes through management of hypertensionJanet B McGill
Therapeutic Advances in Endocrinology and Metabolism|November 28, 2012
Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trialsJanet B McGill
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 15, 2014
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewJanet B McGill
Postgraduate Medicine|June 12, 2014
Anti-diabetes therapy: safety considerations for patients with impaired kidney functionJanet B McGill
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 28, 2015
MAXIMIZING PATIENT SAFETY WITH NEWLY APPROVED THERAPIES: FOCUS ON SGLT2 INHIBITORSJanet B McGill
The Journal of Family Practice|September 12, 2009
Selecting among ADA/EASD tier 1 and tier 2 treatment optionsJanet B McGill
Current Diabetes Reviews|April 21, 2012
Pharmacotherapy in type 2 diabetes: a functional schema for drug classificationJanet B McGill
Vascular Health and Risk Management|June 12, 2010
Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalenceJanet B McGill
Postgraduate Medicine|June 4, 2009
Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studiesJanet B McGill
Postgraduate Medicine|January 31, 2009
Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetesJanet B McGill
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
Postgraduate Medicine|April 1, 2009
Improving microvascular outcomes in patients with diabetes through management of hypertensionJanet B McGill
Therapeutic Advances in Endocrinology and Metabolism|November 28, 2012
Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trialsJanet B McGill
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 15, 2014
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewJanet B McGill
Postgraduate Medicine|June 12, 2014
Anti-diabetes therapy: safety considerations for patients with impaired kidney functionJanet B McGill
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 28, 2015
MAXIMIZING PATIENT SAFETY WITH NEWLY APPROVED THERAPIES: FOCUS ON SGLT2 INHIBITORSJanet B McGill
The Journal of Family Practice|September 12, 2009
Selecting among ADA/EASD tier 1 and tier 2 treatment optionsJanet B McGill
Current Diabetes Reviews|April 21, 2012
Pharmacotherapy in type 2 diabetes: a functional schema for drug classificationJanet B McGill
Vascular Health and Risk Management|June 12, 2010
Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalenceJanet B McGill
Postgraduate Medicine|June 4, 2009
Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studiesJanet B McGill
Postgraduate Medicine|January 31, 2009
Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetesJanet B McGill
Pageof 21